The global hemostasis and tissue sealing agents market size was estimated to be USD 8.04 billion in 2023 and is predicted to reach USD 20.64 billion by 2034 with a CAGR of 8.95% during the forecast period 2024-2034. The rising number of surgical procedures, high prevalence of chronic diseases, technological advancements, increasing use of minimally invasive surgeries, and strategic collaborations and partnerships will drive market growth.
The increasing number of surgical procedures conducted around the world is a significant market driver. As the world population ages and chronic diseases become more common, the need for procedures is likely to increase. Hemostasis and tissue-sealing agents are critical tools for surgeons because they help reduce bleeding during procedures. For instance, in October 2023, Advanced Medical Solutions Group plc announced the launch of Surgiflo, a next-generation hemostatic patch, in select European regions. Surgiflo is intended to prevent bleeding and control leaking during a variety of surgical operations.
By product, the topical hemostat segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agents market in 2023 owing to the advancements in hemostatic technologies, increased surgical procedures, and a growing emphasis on effective bleeding control in various medical specialties. For instance, in July 2023, Baxter International Inc. received FDA 510(k) clearance for their Evicel Fibrin Sealant Patch, a resorbable patch intended to stop bleeding in a variety of surgical settings. Additionally, the adhesive & tissue sealant segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for advanced wound closure solutions, rising adoption of minimally invasive surgeries, and continuous innovations in adhesive and tissue sealant technologies.
By material, the gelatin-based topical hemostats segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agents market in 2023 owing to the biocompatibility, ease of use, and effective hemostatic properties, driving increased adoption in diverse surgical applications and procedures. For instance, in September 2023, B. Braun Melsungen AG announced a strategic collaboration with a prominent medical technology firm to develop and market next-generation hemostatic medicines for less invasive operations. Additionally, the collagen-based topical hemostats segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for natural biomaterials, increased focus on wound healing applications, and ongoing research and development initiatives enhancing the efficacy of collagen-based topical hemostats.
By application, the general surgery segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agents market in 2023 owing to the extensive use of hemostasis and tissue sealing agents in a wide range of general surgical procedures, including abdominal, vascular, and thoracic surgeries, reflecting their crucial role in promoting effective hemostasis and tissue sealing. For instance, in February 2023, Ethicon introduced a new hemostatic patch, Surgicel FLO, in the United States. Surgical FLO is intended for general oozing and bleeding control during laparoscopic and open procedures. Additionally, the collagen-based topical hemostats segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of collagen's hemostatic efficacy, biocompatibility, and versatility, driving its adoption in diverse medical applications and contributing to sustained market growth.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agent market in 2023 owing to the high volume of surgical procedures performed in hospital settings, coupled with the consistent demand for hemostasis and tissue sealing agents across various specialties, emphasizing their critical role in patient care. For instance, Integra LifeSciences completed the acquisition of Surgical Innovation Associates in December 2022, resulting in a strategic expansion of its surgical solutions portfolio. This acquisition strengthens Integra's position in the medical device sector and emphasizes its commitment to driving surgical innovation. Additionally, the ambulatory surgical centers (ASCs) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards outpatient surgical procedures, advancements in minimally invasive techniques suitable for ASCs, and the emphasis on cost-effective and efficient healthcare delivery in these settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, a high prevalence of chronic diseases necessitating surgical interventions, and robust research and development activities fostering innovation in hemostasis and tissue sealing agents within the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing healthcare investments, a rising geriatric population, expanding access to advanced medical technologies, and a growing number of surgical procedures in the Asia Pacific region. For instance, in November 2023, Johnson & Johnson's MedTech business, Ethicon, introduced Ethizia, a hemostatic sealing patch, getting European approval for its introduction, giving a significant boost to their medical services in Europe.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The increasing number of surgical procedures conducted around the world is a significant market driver. As the world population ages and chronic diseases become more common, the need for procedures is likely to increase. Hemostasis and tissue-sealing agents are critical tools for surgeons because they help reduce bleeding during procedures. For instance, in October 2023, Advanced Medical Solutions Group plc announced the launch of Surgiflo, a next-generation hemostatic patch, in select European regions. Surgiflo is intended to prevent bleeding and control leaking during a variety of surgical operations.
By product, the topical hemostat segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agents market in 2023 owing to the advancements in hemostatic technologies, increased surgical procedures, and a growing emphasis on effective bleeding control in various medical specialties. For instance, in July 2023, Baxter International Inc. received FDA 510(k) clearance for their Evicel Fibrin Sealant Patch, a resorbable patch intended to stop bleeding in a variety of surgical settings. Additionally, the adhesive & tissue sealant segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for advanced wound closure solutions, rising adoption of minimally invasive surgeries, and continuous innovations in adhesive and tissue sealant technologies.
By material, the gelatin-based topical hemostats segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agents market in 2023 owing to the biocompatibility, ease of use, and effective hemostatic properties, driving increased adoption in diverse surgical applications and procedures. For instance, in September 2023, B. Braun Melsungen AG announced a strategic collaboration with a prominent medical technology firm to develop and market next-generation hemostatic medicines for less invasive operations. Additionally, the collagen-based topical hemostats segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for natural biomaterials, increased focus on wound healing applications, and ongoing research and development initiatives enhancing the efficacy of collagen-based topical hemostats.
By application, the general surgery segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agents market in 2023 owing to the extensive use of hemostasis and tissue sealing agents in a wide range of general surgical procedures, including abdominal, vascular, and thoracic surgeries, reflecting their crucial role in promoting effective hemostasis and tissue sealing. For instance, in February 2023, Ethicon introduced a new hemostatic patch, Surgicel FLO, in the United States. Surgical FLO is intended for general oozing and bleeding control during laparoscopic and open procedures. Additionally, the collagen-based topical hemostats segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of collagen's hemostatic efficacy, biocompatibility, and versatility, driving its adoption in diverse medical applications and contributing to sustained market growth.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global hemostasis and tissue sealing agent market in 2023 owing to the high volume of surgical procedures performed in hospital settings, coupled with the consistent demand for hemostasis and tissue sealing agents across various specialties, emphasizing their critical role in patient care. For instance, Integra LifeSciences completed the acquisition of Surgical Innovation Associates in December 2022, resulting in a strategic expansion of its surgical solutions portfolio. This acquisition strengthens Integra's position in the medical device sector and emphasizes its commitment to driving surgical innovation. Additionally, the ambulatory surgical centers (ASCs) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards outpatient surgical procedures, advancements in minimally invasive techniques suitable for ASCs, and the emphasis on cost-effective and efficient healthcare delivery in these settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, a high prevalence of chronic diseases necessitating surgical interventions, and robust research and development activities fostering innovation in hemostasis and tissue sealing agents within the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing healthcare investments, a rising geriatric population, expanding access to advanced medical technologies, and a growing number of surgical procedures in the Asia Pacific region. For instance, in November 2023, Johnson & Johnson's MedTech business, Ethicon, introduced Ethizia, a hemostatic sealing patch, getting European approval for its introduction, giving a significant boost to their medical services in Europe.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Product, Material, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Hemostasis and Tissue Sealing Agents Market Report 2023 - 2034
Hemostasis and Tissue Sealing Agents Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Topical Hemostat
- Adhesive and Tissue Sealant
Hemostasis and Tissue Sealing Agents Market Analysis & Forecast by Material 2023 - 2034 (Revenue USD Bn)
- Gelatin-based Topical Hemostats
- Collagen-based Topical Hemostats
- ORC-based Topical Hemostats
- Polysaccharide-based Topical Hemostats
Hemostasis and Tissue Sealing Agents Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- General Surgery
- Neurosurgery
- Vascular Surgery
- Cardiovascular Surgery
- Others
Hemostasis and Tissue Sealing Agents Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Ambulatory Surgical Centers
- Others
Hemostasis and Tissue Sealing Agents Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Hemostasis and Tissue Sealing Agents Market: Product Estimates & Trend Analysis
8. Hemostasis and Tissue Sealing Agents Market: Material Estimates & Trend Analysis
9. Hemostasis and Tissue Sealing Agents Market: Application Estimates & Trend Analysis
10. Hemostasis and Tissue Sealing Agents Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Hemostasis and Tissue Sealing Agents Market
13. Europe Hemostasis and Tissue Sealing Agents Market
14. Asia Pacific Hemostasis and Tissue Sealing Agents Market
15. Latin America Hemostasis and Tissue Sealing Agents Market
16. MEA Hemostasis and Tissue Sealing Agents Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Advanced Medical Solutions Group plc (AMS)
- Baxter International Inc.
- B. Braun Melsungen AG
- BD (Becton
- Dickinson and Company)
- CryoLife Inc.
- Ethicon (Johnson & Johnson Medical)
- GELITA MEDICAL GmbH
- Medtronic plc
- Pfizer Inc.
- Smith & Nephew plc
- Stryker Corporation
- C. R. Bard Inc.
- Integra LifeSciences Corporation
- Cohera Medical Inc.
- Cohesion Technologies Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 8.04 Billion |
| Forecasted Market Value ( USD | $ 20.64 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
